Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.

[1]  S. Rodenhuis,et al.  Clinical significance of ras oncogene activation in human lung cancer. , 1992, Cancer research.

[2]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[3]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[5]  P. Kvale,et al.  In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. , 2004, Journal of clinical epidemiology.

[6]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[7]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[9]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[10]  D. Swinson,et al.  Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer , 2004, British Journal of Cancer.

[11]  M Paesmans,et al.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis , 2004, British Journal of Cancer.

[12]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[14]  K. Aldape,et al.  PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. , 2005, Human pathology.

[15]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[16]  P. Jänne,et al.  Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Varella‐Garcia,et al.  Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay , 2006, Diagnostic pathology.

[18]  P. Jänne,et al.  Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2006, Clinical Cancer Research.

[19]  R. Guo,et al.  Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. , 2006, Lung cancer.

[20]  J. Minna,et al.  Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features , 2006, Clinical Cancer Research.

[21]  H. Dressman,et al.  Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[23]  C. Miller,et al.  PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. , 2007, Oncology reports.

[24]  Janakiraman Subramanian,et al.  Lung cancer in never smokers: a review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Jackson,et al.  Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. , 2007, Carcinogenesis.

[26]  Lesley Seymour,et al.  Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Giaccone,et al.  Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Jänne,et al.  Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[30]  R. Herbst,et al.  Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[32]  C. Pirker,et al.  EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases , 2009, Clinical Cancer Research.

[33]  S. Baker,et al.  PTEN and the PI3-kinase pathway in cancer. , 2009, Annual review of pathology.

[34]  G. Scagliotti,et al.  Histologic subtype in NSCLC: does it matter? , 2009, Oncology.

[35]  M. Meyerson,et al.  PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. , 2009, Cancer research.

[36]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[37]  9161 FLEX study: Prognostic factors in NSCLC , 2009 .

[38]  C. Bokemeyer,et al.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  L. Tanoue,et al.  The new lung cancer staging system. , 2009, Chest.

[40]  W. Pao,et al.  KRAS mutations in non-small cell lung cancer. , 2009, Proceedings of the American Thoracic Society.

[41]  Robert Pirker,et al.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial , 2009, The Lancet.

[42]  M. Gaub,et al.  Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping , 2009, British Journal of Cancer.

[43]  Gregory J Riely,et al.  Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials , 2009, Clinical Cancer Research.

[44]  9160 Molecular and clinical biomarkers of outcome with cetuximab: Data from the phase III FLEX study in non-small cell lung cancer (NSCLC) , 2009 .

[45]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[46]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Caprioli,et al.  Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[48]  C. Horak,et al.  Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Shuhang Wang,et al.  EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. , 2010, Lung cancer.

[50]  Edward S. Kim,et al.  Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  M. Socinski,et al.  If histology matters... , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  R. Goldberg,et al.  TREATMENT OF METASTATIC COLORECTAL CANCER Review of recent advances , 2005 .

[53]  C. Horak,et al.  The cetuximab experience: developing predictive biomarkers in oncology. , 2011, Personalized medicine.

[54]  K. O'Byrne,et al.  First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. , 2011, The Lancet. Oncology.